CLINICAL_TRIALS
trial_result
· 2025-12-04
Clinical Trial Update: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis [Phase 2]
Summary
A Phase 2 trial of Peresolimab (LY3462817) in moderately-to-severely active rheumatoid arthritis was terminated, and results were posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Rheumatoid Arthritis, Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2025-12-04